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METHODS: Il4ra

F709
, Il4ra
Stat6
-/-, Il4ra 
St2
-/-mice were employed. Spontaneous itching, skin water loss, and the status of T-cell, Innate Lymphoid Cell 2 (ILC2) and dendritic cell (DC) activation were analyzed. Bone marrow chimera studies were conducted to determine the contribution of the hematopoietic and stromal compartments to disease. RESULTS: Whereas the Il4ra F709 mice are phenotypically normal, Il4ra
F709
Stat6
-/-progressively develop a spontaneous inflammatory skin disease characterized by severe itching, eczematous skin lesions with eosinophilic and lymphocytic infiltration and excessive water loss. Affected mice exhibited increased ILC2 and IL-13/IL-17 expressing Th cells in the draining lymph nodes in the face of a suppressed IgE response. The skin disease was attenuated but not abolished in Il4ra 
-/-
Rag
-/-mice. Deletion of ST2, encoding the IL-33R, completely abrogated disease in those mice. Bone marrow chimera studies indicated that disease initiation maps to the stromal but not hematopoietic compartment. CONCLUSIONS: STAT6-independent IL-4R signaling in stromal skin elements initiates an IL-33-dependent inflammatory skin disorder that phenocopies many features of eczema. The role of individual cellular components, including keratinocytes and neurons, and IL-4R-coupled signaling pathways in disease pathogenesis is currently under investigation. Regeneron Pharmaceuticals, Inc., Tarrytown, NY. RATIONALE: Dupilumab, a fully human anti-interleukin (IL)-4 receptor a monoclonal antibody, inhibits signaling of IL-4 and IL-13, key drivers of type 2-mediated inflammation. Dupilumab is approved for treatment of inadequately controlled, moderate-to-severe atopic dermatitis (AD) in adults. We assessed dupilumab's efficacy in adults with concurrent AD, asthma, and chronic nasal/paranasal sinus conditions (N/PNS) from four phase 3 trials: LIBERTY AD SOLO 1 & 2 (NCT02277743, NCT02277769), CHRONOS (NCT02260986), and CAF E (NCT02755649). METHODS: Data were pooled from patients with moderate-to-severe AD, asthma requiring treatment plus baseline Asthma Control Questionnaire (ACQ-5) score > _ 0.5, and N/PNS (12.7% of study patients).
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Patients received subcutaneous dupilumab 300 mg every 2 weeks (q2w; n 5 95) or weekly (qw; n 5 102) or placebo (n 5 114). Outcomes were assessed at Week 16: for asthma, by ACQ-5; for N/PNS, by 22-item SinoNasal Outcome Test (SNOT-22); and for AD, by Eczema Area and Severity Index (EASI) and peak pruritus Numerical Rating Scale (NRS). Safety was assessed. RESULTS: Baseline characteristics were consistent with those of the overall study populations. Dupilumab q2w/qw vs placebo improved scores (presented as least squares mean reduction from baseline) on the ACQ-5 (0.53/0.66 vs 0.24; P 5 0.0242/0.0007), .39 vs 6.47; P 5 0.0110/0.0017), EASI (77.7%/75.3% vs 35.5%; P < 0.0001), and peak pruritus NRS (46.1%/50.7% vs 24%; P < 0.0001). Injection-site reactions and conjunctivitis were more common in dupilumab-treated than placebotreated patients.
CONCLUSIONS: This subgroup analysis shows that dupilumab-treated AD patients with asthma and N/PNS experienced clinically and statistically significant improvement in all three diseases.
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Skin lipid abnormalities in patients with a history of eczema herpeticum indicate the involvement of the sphingosine-1-phosphate signaling system In HSV viral replication Evgeny Berdyshev, PhD, Elena Goleva, PhD, John Jung, BS, Irina Bronova, PhD, Kathryn A. Norquest, MS, Brittany N. Richers, BS, and Donald Y. M. Leung, MD, PhD, FAAAAI; National Jewish Health, Denver, CO. RATIONALE: Atopic dermatitis (AD) patients with eczema herpeticum (EH) can result in systemic infections and can be life-threatening. The purpose of this study was to use a novel minimally invasive skin tape strip (STS) methodology to identify differences in non-lesional skin between AD with a history of recurrent EH (ADEH+), AD without EH (ADEH-), and non-atopic (NA) controls to gain insight into mechanisms involved in EH pathogenesis. METHODS: STS layers 5-6 from 13 NA, 13 ADEH-, and 15 ADEH+ adult subjects were collected from non-lesional skin. AD subjects were balanced by gender, race, and age. STS were subjected to lipidomic analyses by mass spectrometry. For the in vitro experiments, differentiated primary human keratinocytes were transfected with control or sphingosine-1-phosphate lyase (S1PL) siRNA for 48h and infected with HSV-1 (0.1 MOI). Viral replication was assessed in 24h with qPCR and plaque assay. RESULTS: ADEH+ but not ADEH-subjects had a significantly increased proportion of short-chain over long-chain non-hydroxy fatty acid sphingosine (NS)-ceramides (p50.002), and increased levels of sphingomyelins (p50.006) as compared to NA subjects. Distinguishably to ADEH-, ADEH+ subjects demonstrated increased level of free C18-sphingosine (p50.007) and elevated free C17-sphingosine (p50.052), suggesting upregulated skin sphingosine-1-phosphate (S1P) metabolism and signaling. Silencing S1PL in vitro resulted in increased viral replication after keratinocyte inoculation with HSV-1 (Median [Q1,Q3] 0.24[0.20;0.29] vs 0.54[047;0.62] for S1PL vs. control siRNA-transfected keratinocytes, p50.05 as detected by qPCR). CONCLUSIONS: STS from ADEH+ subjects and in vitro studies indicate involvement of the S1P signaling system in EH and suggest novel therapeutic targets to treat EH.
